US 12016904
Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
granted A61KA61K38/36A61K38/37
Quick answer
US patent 12016904 (Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF) held by Takeda Pharmaceutical Company Limited expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K38/36, A61K38/37, A61P, A61P7/04